raw materials – Page 20

Change control documentation gaps during post-approval change review – regulatory expectations for material changes

Addressing Documentation Gaps in Change Control During Post-Approval Material Changes In the ever-evolving landscape of pharmaceutical manufacturing, change control is a critical process that ensures quality and compliance. However, as…

Critical supplier risk not assessed during supplier onboarding – evidence pack for vendor oversight

Assessing Critical Supplier Risks During Onboarding: An Investigative Approach In a highly regulated pharmaceutical landscape, the onboarding process for suppliers plays a critical role in ensuring consistent quality and compliance.…

Change control documentation gaps during supplier change – CAPA to prevent repeat failures

Addressing Gaps in Change Control Documentation During Supplier Transitions In the dynamic pharmaceutical landscape, managing supplier changes is critical for maintaining product quality and regulatory compliance. Frequently, organizations face challenges…

Supplier audit findings escalated during routine supplier audit – how to prevent repeat supplier failures

Addressing Escalated Supplier Audit Findings for Continuous Quality Improvement Supplier audits are vital to maintaining the integrity of pharmaceutical manufacturing processes. When findings escalate during routine assessments, it can indicate…

Supplier change not evaluated during post-approval change review – CAPA to prevent repeat failures

Effective Management of Supplier Changes Post-Approval to Prevent Repeated Failures Pharmaceutical manufacturing demands strict adherence to regulatory standards, especially when it comes to raw material change control. A frequent issue…

Critical supplier risk not assessed during supplier onboarding – supplier risk classification strategy

Assessing Critical Supplier Risk During Onboarding: A Comprehensive Investigation In the pharmaceutical industry, the onboarding process of suppliers is critical to maintaining product quality and compliance. An oversight in assessing…

Change impact underestimated during supplier change – regulatory expectations for material changes

Understanding Change Impact During Supplier Transitions in Pharma: A Practical Playbook The pharmaceutical industry operates under a strict regulatory framework that mandates thorough assessments of any changes in raw materials,…

Vendor change implemented without approval during supplier onboarding – inspection questions regulators ask

Investigating Unapproved Vendor Changes During Supplier Onboarding In the pharmaceutical industry, the integrity of raw materials is critical to the safety, efficacy, and quality of products. An investigation into the…

Unapproved material substitution during routine operations – CAPA to prevent repeat failures

Playbook for Addressing Unapproved Material Substitution in Routine Operations In the pharmaceutical landscape, unapproved material substitution during routine operations poses significant risks to product quality and regulatory compliance. It can…

Supplier audit findings escalated during supply disruption – audit CAPA remediation framework

Escalated Supplier Audit Findings During Supply Disruption: An Investigative Framework for CAPA Remediation In a landscape where supply chain robustness is paramount, the escalating findings from supplier audits can signal…

Unapproved material substitution during post-approval change review – CAPA to prevent repeat failures

Managing Unapproved Material Substitution in Post-Approval Change Reviews Unapproved material substitutions during post-approval changes pose significant risks to product quality and compliance. This situation often arises in the lifecycle of…

Supplier audit findings escalated during supplier onboarding – audit CAPA remediation framework

Framework for Remediating Supplier Audit Findings During Onboarding In the pharmaceutical industry, supplier audits are critical for ensuring the quality and compliance of raw materials. Issues identified during audits can…